ReviewJournal of cardiovascular development and disease2026
Diagnosis and Management of Patients with Patent Foramen Ovale: Current Evidence and Future Perspective.
Review in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patent foramen ovale (PFO) is a condition present in 20-25% of the general population and can rarely be associated with clinical conditions such as stroke, decompression sickness, desaturation, and migraine with aura. Screening for PFO for primary prevention is not recommended. Several trials have been published demonstrating the efficacy of percutaneous PFO closure in patients under 60 years of age with embolic stroke of unknown etiology. Such evidence has not been achieved in other patient groups, such as those with migraine with aura or decompression sickness. There is also a subset of patients, such as pregnant women or patients undergoing laparoscopic non-cardiac surgery, in whom an increased risk of paradoxical embolism requires preoperative stratification. In all cases, it is necessary to characterize the PFO based on the size of the shunt and the anatomy (e.g., the presence of a large tunnel, prominent Eustachian valve, atrial septal aneurysm), all factors that can increase the risk of paradoxical embolism. This review summarizes the current view on diagnostic and therapeutic work-up of PFO in light of the most recent international guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.